Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JX3U | ISIN: US8684591089 | Ticker-Symbol: S49
Frankfurt
27.06.25 | 08:02
26,600 Euro
0,00 % 0,000
1-Jahres-Chart
SUPERNUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SUPERNUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
26,40026,60028.06.
26,60026,80027.06.

Aktuelle News zur SUPERNUS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.06.Supernus to acquire Sage Therapeutics stock for $8.50 per share18
SUPERNUS Aktie jetzt für 0€ handeln
17.06.SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal1
17.06.Truist raises Sage Therapeutics price target on Supernus acquisition4
17.06.Supernus stock rating reiterated as Piper Sandler questions Sage deal2
17.06.Supernus buys Sage Therapeutics for $561 million as Cantor holds rating1
16.06.Supernus makes depression drug play with $795m Sage buyout1
16.06.Sage, following Setbacks, to sell to Supernus for $561M2
16.06.Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae5
16.06.After rebuffing Biogen, Sage pairs off with Supernus9
16.06.Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal1
16.06.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
16.06.Biotech-Übernahme! SUPERNUS PHARMA kauft SAGE THERAPEUTICS!9
16.06.Supernus To Acquire Sage Therapeutics; Strengthens Psychiatry Portfolio With ZURZUVAE Capsules CIV263WESTON (dpa-AFX) - Supernus Pharmaceuticals (SUPN) and Sage Therapeutics (SAGE) announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash...
► Artikel lesen
16.06.Supernus to acquire depression drugmaker Sage2
16.06.Supernus to acquire Sage Therapeutics for up to $795 million7
16.06.Supernus Pharmaceuticals, Inc. to Acquire Sage Therapeutics, Inc., Strengthening its Neuropsychiatry Product Portfolio131Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with...
► Artikel lesen
29.05.Supernus Pharmaceuticals, Inc.: Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree Content Series with Supernus Pharmaceuticals1
28.05.Supernus Pharmaceuticals, Inc.: Supernus Announces Paragraph IV ANDA Filings for Qelbree2
28.05.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
21.05.Supernus casts Busy Philipps as 'Ms. Represented' in Qelbree campaign targeting women with ADHD2
Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1